- Trial phase
- Phase 3 (paused)
- Time to market
- Uncertain. The Phase 3 trial is paused due to insufficient capital, and the company is seeking a partner to continue development. Even if partnered, a pivotal trial would need to complete before any regulatory filing, putting potential approval years away.
- Why 3/10
- No hard, dated catalyst is scheduled for TSC-101 in the next ~12 months. The Phase 3 ALLOHA-2 trial was paused in September 2026 due to insufficient capital, and the company is seeking a partner. Without a pending PDUFA, pivotal readout, or AdComm, the impact score cannot exceed 5 per the rubric.
TSC-101's development is paused, and the stock's fate hinges entirely on whether TScan can secure a partnership for the heme program. Without a partner, the Phase 3 trial will not resume and the program may be abandoned. The company's focus has shifted to preclinical solid tumor candidates, which are years from clinical data. Monitor for partnership announcements or a potential sale of the heme assets.
Price Chart
Executive Summary
TSC-101 is TScan Therapeutics' lead TCR-T cell therapy for acute myeloid leukemia and myelodysplastic syndromes. It showed promising Phase 1 data in June 2026 and entered a Phase 3 pivotal trial in July 2026. However, in September 2026, TScan cut 75% of its workforce, paused the Phase 3 ALLOHA-2 trial, and pivoted to preclinical solid tumor programs, citing insufficient capital. The stock trades around $0.16 with a ~$11.5M market cap. Multiple analysts downgraded the stock in September 2026. TSC-101's future now depends on the company finding a partner to continue development.
How It Works
TSC-101 is an engineered T cell receptor (TCR) therapy. It takes a patient's or donor's immune T cells and genetically modifies them to recognize the HA-2 antigen, a protein found on the surface of blood cancer cells (acute myeloid leukemia and myelodysplastic syndromes). The modified cells are infused into the patient after a bone marrow transplant to seek out and destroy residual cancer cells while leaving healthy tissue alone.
Trial Status
TSC-101 completed Phase 1 ALLOHA trial with positive data from Cohort C in June 2026 (11 of 14 patients achieved complete donor chimerism within ~3 weeks). The Phase 3 ALLOHA-2 pivotal trial began dosing in July 2026, but enrollment was paused in September 2026 when TScan announced a strategic reorganization cutting 75% of its workforce and shifting focus to solid tumor programs. The company is actively seeking partnerships for the heme program including TSC-101.
The Two-Sided Case
Upcoming Catalysts
- Partnership or licensing deal for the heme program (including TSC-101)
- Potential restart of Phase 3 ALLOHA-2 enrollment if partnered
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TScan Therapeutics, Inc. 8-K TCRX ·Originating report